Who owns APIMEDS PHARMACEUTICALS US I COM?
- Ticker: APUS
- CUSIP Number: 03771d102
Tip: Access positions for across all investors
Analyze quarterly positions in Apimeds Pharmaceuticals Us I with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Apimeds Pharmaceuticals Us I stock
Who bought or sold APIMEDS PHARMACEUTICALS US I COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Hemenway Trust Company | 274k | $490k | 0% | Mar 2026 |
|
| Vanguard Capital Management | 96k | $172k | 100% | Mar 2026 |
|
| Vanguard Group | 59k | $97k | 0% | Dec 2025 |
|
| Geode Capital Management | 40k | $72k | 15% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 24k | $43k | 100% | Mar 2026 |
|
| Two Sigma Securities | 11k | $19k | 100% | Mar 2026 |
|
| UBS Group | 4.2k | $7.5k | 619% | Mar 2026 |
|
| Tower Research Capital | 10.00 | $16.000000 | 100% | Dec 2025 |
|
Who sold out of Apimeds Pharmaceuticals Us I?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Renaissance Technologies | Sep 2025 | 28k | $50k |
| Jane Street | Dec 2025 | 27k | $45k |
| XTX Topco | Sep 2025 | 19k | $33k |